Shockwave Medical Inc (SWAV)
330.61
+0.61
(+0.18%)
USD |
NASDAQ |
May 07, 12:55
Shockwave Medical Research and Development Expense (Quarterly): 42.32M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 42.32M |
| September 30, 2023 | 39.53M |
| June 30, 2023 | 36.83M |
| March 31, 2023 | 26.97M |
| December 31, 2022 | 23.72M |
| September 30, 2022 | 20.18M |
| June 30, 2022 | 20.76M |
| March 31, 2022 | 17.02M |
| December 31, 2021 | 14.72M |
| September 30, 2021 | 13.74M |
| June 30, 2021 | 11.82M |
| March 31, 2021 | 10.28M |
| Date | Value |
|---|---|
| December 31, 2020 | 9.044M |
| September 30, 2020 | 7.891M |
| June 30, 2020 | 8.101M |
| March 31, 2020 | 11.89M |
| December 31, 2019 | 10.08M |
| September 30, 2019 | 8.368M |
| June 30, 2019 | 6.926M |
| March 31, 2019 | 7.484M |
| December 31, 2018 | 6.119M |
| September 30, 2018 | 5.533M |
| June 30, 2018 | 5.53M |
| March 31, 2018 | 5.516M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.926M
Minimum
Jun 2019
42.32M
Maximum
Dec 2023
17.90M
Average
13.74M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp | 366.00M |
| AtriCure Inc | 19.84M |
| Masimo Corp | 38.00M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |